CG Oncology appoints Jim DeTore as CFO with $520K base and $5M equity

CG Oncology, Inc.

Jim DeTore, age 61, appointed CFO effective April 13, 2026; previously served as interim principal financial officer since Nov 2025.
Initial annual base salary of $520,000 with target bonus of 45% of base salary.
Equity grants: $4M stock option (4-year vest, 25% one-year cliff) and $1M PSU award (vesting on first U.S. commercial sale and positive operating cash flow).
Severance includes 12 months base salary and COBRA for non-CIC terminations; 1.5x base salary and full vesting for CIC terminations.
DeTore reports to CEO and will work remotely from Boston area.

item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-152044
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2026-04-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.356707+00:00
generated_at: 2026-05-15T06:37:37.600440+00:00
sec_items: ["5.02", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-152044
json_url: https://secwatch.observer/filing/0001193125-26-152044.json
markdown_url: https://secwatch.observer/filing/0001193125-26-152044.md
text_url: https://secwatch.observer/filing/0001193125-26-152044.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526152044/0001193125-26-152044-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526152044/ck0001991792-20260413.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-152044

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.